“We are excited by the progress of our pipeline and believe our next-generation immunotherapies have the power to address significant unmet patient needs,” said Andrew Schiermeier, Ph.D., Chief Executive Officer, AvenCell Therapeutics. “AvenCell is working to transform the standard of care through switchable, adaptable and readily available cell therapy treatments that can better treat a wide range of difficult-to-treat cancer and autoimmune diseases. The support of Novo Holdings and this leading group of new investors will be integral to our ability to progress and bring these therapies to patients.”